St. Peters Hospital
- Type
- Teaching hospital
- Where
- Albany, NY
- Medicare CCN
- 330057
- Received
- $7,580 in 4 records, 2024 ($5,000 general, $2,580 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit: ST PETERS HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 1 | $5,000 |
| 2024 | Research payment | 3 | $2,580 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Tanabe Pharma America, Inc. | 1 | $5,000 | 2024 |
| Merck Sharp & Dohme LLC | 1 | $2,500 | 2024 |
| Abbott Laboratories | 2 | $80 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Space rental or facility fees (teaching hospital only) | 1 | $5,000 |
| Research payment | 3 | $2,580 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-10-10 | Tanabe Pharma America, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RADICAVA ORS Drug, AMYOTROPHIC LATERAL SCLEROSIS | 2024 | |
| 2024-05-31 | Merck Sharp & Dohme LLC | $2,500 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with | 2024 |
| 2024-04-15 | Abbott Laboratories | $50 | Research payment | In-kind items and services | ASSERT-IQ Device, VASCULAR | Assert-IQ Insertable Cardiac Monitor Post Market Study | 2024 |
| 2024-04-15 | Abbott Laboratories | $30 | Research payment | In-kind items and services | ASSERT-IQ Device, VASCULAR | Assert-IQ Insertable Cardiac Monitor Post Market Study | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
Comments